Corresponding human studies have been conducted mostly in patients with T2DM [17], metabolic syndrome [18], [19], coronary heart disease [18], osteoporosis therapy [20] or hypertension [19], and these have witnessed low osteocalcin to associate with higher fasting plasma insulin, glucose and triglyceride levels without proof of causality. This evidence concerns the gene BGLAP and coronary artery disorder.